Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination and Validation of Lung EpiCheck®: A Multianalyte Assay for Lung Cancer Prediction. A Case-Control Study

NCT04968548 is registered in ClinicalTrials.gov with Nucleix Ltd. as lead sponsor.

NCT NCT04968548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04968548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination and Validation of Lung EpiCheck®: A Multianalyte Assay for Lung Cancer Prediction. A Case-Control Study
Lead sponsor
Nucleix Ltd.
Phase
Observational
Overall status
Completed
Start date
September 17, 2021
Completion date
December 31, 2025
Enrollment
6,182 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer